Literature DB >> 30259848

Current Treatment Options for Primary Biliary Cholangitis.

Kimberly A Wong1, Runalia Bahar1, Chung H Liu2, Christopher L Bowlus3.   

Abstract

Primary biliary cholangitis is a progressive, autoimmune disease of the interlobular bile ducts, leading to secondary damage of hepatocytes that may progress to cirrhosis and liver failure. Until recently, the only approved treatment was ursodeoxycholic acid. However, 40% of patients do not have an adequate response. Obeticholic acid was approved for treatment as add-on therapy in this group of patients. Off-label use of fibrates has also been reported to be effective. Several new therapies are in development and may further add to the treatment options available to patients with primary biliary cholangitis.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoimmune liver disease; Bile acids; Farnesoid X receptor; Therapy

Mesh:

Substances:

Year:  2018        PMID: 30259848     DOI: 10.1016/j.cld.2018.03.003

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  4 in total

1.  A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist.

Authors:  Fernanda Q Onofrio; Gideon M Hirschfield; Aliya F Gulamhusein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-03

2.  Serum Ghrelin Concentration in Patients With Primary Biliary Cirrhosis (PBC).

Authors:  Rania Naguib; Amel Fayed; Eman Elkemary; Hend Naguib
Journal:  Cureus       Date:  2021-12-09

3.  Disease burden of primary biliary cholangitis and associated pruritus based on a cross-sectional US claims analysis.

Authors:  Usha Gungabissoon; Daniel C Gibbons; Gema Requena; Andrea Ribeiro de Souza; Helen Smith
Journal:  BMJ Open Gastroenterol       Date:  2022-08

4.  Treatment of primary biliary cirrhosis with ursodeoxycholic acid combined with traditional Chinese medicine: A protocol for systematic review and meta analysis.

Authors:  Xing Chen; Xiao Ma; Ruilin Wang; Lifu Wang; Jianyu Li; Honghong Liu; Tingting He; Shizhang Wei; Haotian Li; Min Wang; Yanling Zhao
Journal:  Medicine (Baltimore)       Date:  2020-11-13       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.